Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Brief Summary: This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.


Options:
A: Arm Label: Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): Ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Placebo, Ramucirumab | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Placebo, Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Placebo, Ramucirumab
B: Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 3mg/kg, Drug: Cisplatin, Drug: Capecitabine | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 10mg/kg, Drug: Cisplatin, Drug: Capecitabine | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386 placebo, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: AMG 386 placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: AMG 386 10mg/kg; Assigned to Arm(s): A | Intervention Type: DRUG; Name: AMG 386 3mg/kg; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): B
C: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Best Supportive Care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus placebo, Drug: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Everolimus placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: DRUG; Name: Best Supportive Care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
D: Arm Label: A1: Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm A2: Capecitabine Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine | Arm Label: Arm A3: MEDI4736 (Durvalumab); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 (Durvalumab) | Arm Label: Arm B1: Trastuzumab Maintenance; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trastuzumab | Arm Label: Arm A4: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Arm A5: Capecitabine and Ramucirumab; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Ramucirumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm A2: Capecitabine Maintenance, Arm A5: Capecitabine and Ramucirumab | Intervention Type: DRUG; Name: MEDI4736 (Durvalumab); Assigned to Arm(s): Arm A3: MEDI4736 (Durvalumab) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Arm B1: Trastuzumab Maintenance | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Arm A4: Rucaparib | Intervention Type: DRUG; Name: Ramucirumab; Assigned to Arm(s): Arm A5: Capecitabine and Ramucirumab

Answer: C